Morphosys AG

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
D55040105
SEDOL
5531000
CIK
N/A
morphosys.com
LEI: 529900493806K77LRE72
©
FIGI: BBG000C68VC2
MOR
Morphosys AG
GICS: 35201010 · Sector: Biotechnology · Sub-Sector: -
AI
PROFILER
NAME
Morphosys AG
ISIN
DE0006632003
TICKER
MOR
MIC
XETR
REUTERS
MORG.DE
BLOOMBERG
MOR GR
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
TradingView ActivTrader MT4 MT5
EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Tue, 27.08.2024

Media Release Planegg/Munich, Germany, August 27, 2024   Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting MorphoSys AG today announced that its shareholders approved all resolutions proposed by the company’s Management Board and Supervisory Board at its 2024 Annual General Meeting. This included the t...
Research & Analysis
Read more
Mon, 05.08.2024

Media Release Planegg/Munich, Germany, August 5, 2024   MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market   MorphoSys AG today announced that it has completed the voluntary delisting of its shares from the Frankfurt Stock Exchange and its American Depositary Shares (“ADSs”) from the Nasdaq Global ...
Research & Analysis
Read more
Fri, 12.07.2024

Media Release Planegg/Munich, Germany, July 12, 2024   MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market   MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (“ADSs”) from the Nasdaq Global Market an...
Research & Analysis
Read more
Fri, 12.07.2024

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Key word(s): Squeeze Out Planegg/Munich, Germany, July 12, 2024   Ad hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00   MorphoSys AG (FSE: MOR; NASDAQ: MOR) announces that Novartis BidCo Germany AG submitted a specified re...
Research & Analysis
Read more
Thu, 20.06.2024

Media Release Planegg/Munich, Germany, June 20, 2024   MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders   MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following t...
Research & Analysis
Read more
Thu, 20.06.2024

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Key word(s): Squeeze Out Planegg/Munich, Germany, June 20, 2024     Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders MorphoSys AG (FSE: MOR; NASDAQ: MOR) announces that Nov...
Research & Analysis
Read more
Thu, 20.06.2024

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Key word(s): Squeeze Out Planegg/Munich, Germany, June 20, 2024     Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders MorphoSys AG (FSE: MOR; NASDAQ: MOR) announces that Nov...
Research & Analysis
Read more
Thu, 06.06.2024

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014   Planegg/Munich, Germany, June 6, 2024     Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO   Following the closing of the takeover offer by Novartis BidCo AG to th...
Research & Analysis
Read more
Mon, 29.04.2024

Media Release Planegg/Munich, Germany, April 29, 2024   MorphoSys AG Reports First Quarter 2024 Financial Results Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash, representing a total equity value of € 2.7 billion Received all mandatory antitrust approvals for the proposed acquisition by Novar...
Research & Analysis
Read more
Wed, 24.04.2024

Media Release Planegg/Munich, Germany, April 24, 2024 MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat  MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced th...
Research & Analysis
Read more
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S